<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460679</url>
  </required_header>
  <id_info>
    <org_study_id>EPI589-15-001</org_study_id>
    <nct_id>NCT02460679</nct_id>
  </id_info>
  <brief_title>Safety and Biomarker Study of EPI-589 in Subjects With ALS</brief_title>
  <acronym>EPI-589</acronym>
  <official_title>A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edison Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label study with EPI-589 and ALS subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label with 30-day run in phase to establish baseline parameters and a 90-day withdrawal
      phase to determine duration of treatment response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of EPI-589 on safety as assessed by drug-related AEs</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the effects of EPI-589 in Subjects with ALS on drug related adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Drug plasma concentration</measure>
    <time_frame>6 months</time_frame>
    <description>Drug plasma concentration measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression as assessed by ALS Functional Rating Scale-Revised</measure>
    <time_frame>6 months</time_frame>
    <description>Disease progression as assessed by ALS Functional Rating Scale-Revised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function assessed by PFTs and capnography</measure>
    <time_frame>6 months</time_frame>
    <description>Respiratory function assessed by PFTs and capnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure to thrive as measured by body weight</measure>
    <time_frame>6 months</time_frame>
    <description>Failure to thrive as measured by body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on swallowing as assessed by change in water and solid swallowing test</measure>
    <time_frame>6 months</time_frame>
    <description>Swallowing as assessed by change in water and solid swallowing test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function as assessed by handheld dynamometry</measure>
    <time_frame>6 months</time_frame>
    <description>Muscle function as assessed by handheld dynamometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech as assessed by speech evaluation</measure>
    <time_frame>6 months</time_frame>
    <description>Speech as assessed by speech evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biomarkers</measure>
    <time_frame>6 months</time_frame>
    <description>Biomarker changes will be measure in blood, cerebrospinal fluid and urine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>EPI-589</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPI-589</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-589</intervention_name>
    <description>An immediate release film-coated table at a 250 mg dosage strength.</description>
    <arm_group_label>EPI-589</arm_group_label>
    <other_name>(R)-troloxamide quinone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dx. of ALS by E1 Escorial Criteria

          -  FVC &gt;= 70% years of age

          -  Weakness onset within 3 years

          -  Agreement to use contraception when age appropriate

          -  Willingness and ability to comply with study procedures

          -  Stable regimen of dietary supplements and /or riluzole for at least 30 days prior to
             study

          -  Absention from use of other investigative or non-approved drugs

          -  Subject must be able to swallow size 0 tablets

        Exclusion Criteria:

          -  Allergy to EPI-589

          -  Use of ventilation

          -  Participation in other intervention studies

          -  Inability to undergo MRI or MRS

          -  Dx with any other neurologic disease

          -  Malignancy within the past 2 years

          -  Hx. of stroke

          -  Hx. of brain injury

          -  Hepatic insufficiency (LFTs &gt; 3 xs ULN)

          -  Renal insufficiency requiring dialysis

          -  End stage cardiac failure

          -  Participation in a trial of a device, drug or other tx. for ALS within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew B Klein, MD, FACS</last_name>
    <role>Study Director</role>
    <affiliation>Edison Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew B Klein, MD, FACS</last_name>
    <phone>650-641-9211</phone>
    <email>mklein@edisonpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin P Johnson, BA</last_name>
    <phone>650-641-9212</phone>
    <email>ejohnson@edisonpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedar's Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Baloh, MD, PhD</last_name>
      <phone>310-825-5910</phone>
      <email>rwbaloh@ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vy Nguyen</last_name>
      <phone>(424)315-2361</phone>
      <email>Vy.NguyenX@cshs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Miller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Brain and Spine Institute ALS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Goslin, MD, PhD</last_name>
      <phone>503-962-1171</phone>
      <email>kimberly.goslin@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Arlena Cummings</last_name>
      <phone>503-962-1171</phone>
      <email>arlena.cummings@providence.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

